share_log

HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Lowers Price Target to $5.5

Benzinga ·  Nov 13, 2023 18:27

HC Wainwright & Co. analyst Oren Livnat maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and lowers the price target from $6 to $5.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment